Achieve Life Sciences, Inc. Logo

Achieve Life Sciences, Inc.

ACHV

(0.0)
Stock Price

3,69 USD

-43.94% ROA

-108.3% ROE

-6.57x PER

Market Cap.

180.978.651,00 USD

41.73% DER

0% Yield

0% NPM

Achieve Life Sciences, Inc. Stock Analysis

Achieve Life Sciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Achieve Life Sciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Negative ROE (-869.25%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (-159.38%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

3 PBV

The stock's elevated P/BV ratio (10.41x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

4 DER

The company has a high debt to equity ratio (163%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Achieve Life Sciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Achieve Life Sciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Achieve Life Sciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Achieve Life Sciences, Inc. Revenue
Year Revenue Growth
1994 1.100.000
1995 4.500.000 75.56%
1996 16.600.000 72.89%
1997 18.900.000 12.17%
1998 5.100.000 -270.59%
1999 12.100.000 57.85%
2000 408.407 -2862.73%
2001 8.748.538 95.33%
2002 25.000 -34894.15%
2003 25.000 0%
2004 264.962.000 99.99%
2005 8.254.483 -3109.92%
2006 22.391.858 63.14%
2007 20.130.663 -11.23%
2008 20.131.000 0%
2009 25.539.000 21.18%
2010 13.616.000 -87.57%
2011 5.496.000 -147.74%
2012 20.095.000 72.65%
2013 29.882.000 32.75%
2014 27.116.000 -10.2%
2015 18.160.000 -49.32%
2016 5.062.000 -258.75%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Achieve Life Sciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1994 0
1995 7.200.000 100%
1996 11.200.000 35.71%
1997 11.600.000 3.45%
1998 10.500.000 -10.48%
1999 5.600.000 -87.5%
2000 3.258.630 -71.85%
2001 5.221.303 37.59%
2002 8.956.755 41.71%
2003 7.653.486 -17.03%
2004 10.706.223 28.51%
2005 24.493.651 56.29%
2006 41.102.276 40.41%
2007 27.146.725 -51.41%
2008 7.819.000 -247.19%
2009 24.160.000 67.64%
2010 18.483.000 -30.71%
2011 21.553.000 14.24%
2012 39.948.000 46.05%
2013 55.317.000 27.78%
2014 46.224.000 -19.67%
2015 25.108.000 -84.1%
2016 14.788.000 -69.79%
2017 3.101.000 -376.88%
2018 5.868.000 47.15%
2019 9.674.000 39.34%
2020 6.882.000 -40.57%
2021 23.966.000 71.28%
2022 30.078.000 20.32%
2023 14.324.000 -109.98%
2023 15.814.000 9.42%
2024 20.452.000 22.68%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Achieve Life Sciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1994 3.500.000
1995 2.200.000 -59.09%
1996 3.810.000 42.26%
1997 7.200.000 47.08%
1998 6.550.000 -9.92%
1999 5.780.000 -13.32%
2000 3.950.000 -46.33%
2001 3.310.000 -19.34%
2002 3.242.342.000 99.9%
2003 3.009.665.000 -7.73%
2004 5.869.331.000 48.72%
2005 5.570.051.000 -5.37%
2006 7.576.276.000 26.48%
2007 8.218.890.000 7.82%
2008 3.293.000 -249486.7%
2009 3.961.000 16.86%
2010 5.840.000 32.17%
2011 0 0%
2012 7.791.000 100%
2013 9.892.000 21.24%
2014 10.625.000 6.9%
2015 11.805.000 10%
2016 8.933.000 -32.15%
2017 3.531.000 -152.99%
2018 6.945.000 49.16%
2019 6.854.000 -1.33%
2020 7.868.000 12.89%
2021 9.128.000 13.8%
2022 10.722.000 14.87%
2023 11.964.000 10.38%
2023 11.436.000 -4.62%
2024 13.272.000 13.83%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Achieve Life Sciences, Inc. EBITDA
Year EBITDA Growth
1994 -8.000.000
1995 -4.900.000 -63.27%
1996 1.300.000 476.92%
1997 -400.000 425%
1998 -12.100.000 96.69%
1999 1.500.000 906.67%
2000 -11.125.204 113.48%
2001 474.449 2444.87%
2002 -11.593.478 104.09%
2003 -10.257.725 -13.02%
2004 -16.060.075 36.13%
2005 -21.227.223 24.34%
2006 -25.564.589 16.97%
2007 -14.453.912 -76.87%
2008 -11.234.000 -28.66%
2009 -2.699.000 -316.23%
2010 -5.692.000 52.58%
2011 -29.606.000 80.77%
2012 -33.660.000 12.04%
2013 -38.308.000 12.13%
2014 -30.000.000 -27.69%
2015 -18.753.000 -59.97%
2016 -16.126.000 -16.29%
2017 838.000 2024.34%
2018 -12.813.000 106.54%
2019 -16.528.000 22.48%
2020 -14.495.000 -14.03%
2021 -33.094.000 56.2%
2022 -40.800.000 18.89%
2023 -26.288.000 -55.2%
2023 -27.022.000 2.72%
2024 -33.844.000 20.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Achieve Life Sciences, Inc. Gross Profit
Year Gross Profit Growth
1994 -4.400.000
1995 4.800.000 191.67%
1996 17.100.000 71.93%
1997 19.500.000 12.31%
1998 5.900.000 -230.51%
1999 12.700.000 53.54%
2000 -3.281.593 487.01%
2001 3.528.538 193%
2002 25.000 -14014.15%
2003 25.000 0%
2004 264.962.000 99.99%
2005 8.254.483 -3109.92%
2006 22.391.858 63.14%
2007 20.130.663 -11.23%
2008 20.131.000 0%
2009 25.539.000 21.18%
2010 13.616.000 -87.57%
2011 5.496.000 -147.74%
2012 20.095.000 72.65%
2013 29.882.000 32.75%
2014 27.116.000 -10.2%
2015 18.160.000 -49.32%
2016 5.062.000 -258.75%
2017 -282.000 1895.04%
2018 -282.000 0%
2019 -254.000 -11.02%
2020 -255.000 0.39%
2021 -250.000 -2%
2022 -236.000 -5.93%
2023 0 0%
2023 -228.000 100%
2024 -228.000 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Achieve Life Sciences, Inc. Net Profit
Year Net Profit Growth
1994 -8.900.000
1995 -5.900.000 -50.85%
1996 1.700.000 447.06%
1997 1.000.000 -70%
1998 -11.200.000 108.93%
1999 400.000 2900%
2000 -2.147.437 118.63%
2001 542.177 496.08%
2002 -11.635.801 104.66%
2003 -10.467.099 -11.17%
2004 -16.310.592 35.83%
2005 -21.097.017 22.69%
2006 -23.551.296 10.42%
2007 -13.063.168 -80.29%
2008 -4.204.000 -210.73%
2009 5.476.000 176.77%
2010 -12.584.000 143.52%
2011 -14.673.000 14.24%
2012 -21.098.000 30.45%
2013 -31.849.000 33.76%
2014 -26.240.000 -21.38%
2015 -16.801.000 -56.18%
2016 -20.129.000 16.53%
2017 -10.583.000 -90.2%
2018 -12.687.000 16.58%
2019 -16.141.000 21.4%
2020 -14.661.000 -10.09%
2021 -32.902.000 55.44%
2022 -41.875.000 21.43%
2023 -28.432.000 -47.28%
2023 -29.815.000 4.64%
2024 -33.844.000 11.9%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Achieve Life Sciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1994 -41.784
1995 -27.700 -50.85%
1996 7.907 450.35%
1997 4.608 -71.57%
1998 -51.613 108.93%
1999 1.915 2796.55%
2000 -8.874 121.57%
2001 1.844 581.18%
2002 -33.727 105.47%
2003 -23.106 -45.96%
2004 -30.261 23.64%
2005 -27.363 -10.59%
2006 -25.324 -8.06%
2007 -13.971 -81.25%
2008 -1.678 -733.09%
2009 1.905 188.03%
2010 -3.939 148.37%
2011 -3.318 -18.69%
2012 -3.433 3.32%
2013 -4.772 28.08%
2014 -3.190 -49.64%
2015 -1.414 -125.69%
2016 -1.479 4.4%
2017 -441 -235.15%
2018 -72 -512.5%
2019 -39 -84.62%
2020 -5 -680%
2021 -4 -25%
2022 -4 -33.33%
2023 -1 -200%
2023 -2 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Achieve Life Sciences, Inc. Free Cashflow
Year Free Cashflow Growth
1994 -4.200.000
1995 -8.100.000 48.15%
1996 3.000.000 370%
1997 200.000 -1400%
1998 -10.800.000 101.85%
1999 -100.000 -10700%
2000 -4.012.757 97.51%
2001 1.061.152 478.15%
2002 -11.304.733 109.39%
2003 -10.596.200 -6.69%
2004 -15.046.626 29.58%
2005 -8.478.656 -77.46%
2006 -20.469.939 58.58%
2007 -24.731.389 17.23%
2008 -12.310.000 -100.9%
2009 34.863.000 135.31%
2010 -26.908.000 229.56%
2011 -20.342.000 -32.28%
2012 -43.784.000 53.54%
2013 -36.180.000 -21.02%
2014 -17.390.000 -108.05%
2015 -9.472.000 -83.59%
2016 -29.729.000 68.14%
2017 -9.107.000 -226.44%
2018 -10.669.000 14.64%
2019 -15.269.000 30.13%
2020 -13.491.000 -13.18%
2021 -29.457.000 54.2%
2022 -37.549.000 21.55%
2023 -5.136.000 -631.09%
2023 -24.500.000 79.04%
2024 -4.921.000 -397.87%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Achieve Life Sciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1994 -3.500.000
1995 -7.800.000 55.13%
1996 3.500.000 322.86%
1997 1.400.000 -150%
1998 -10.300.000 113.59%
1999 -100.000 -10200%
2000 -3.974.091 97.48%
2001 1.249.334 418.1%
2002 -10.399.800 112.01%
2003 -9.909.564 -4.95%
2004 -14.620.625 32.22%
2005 -8.359.213 -74.9%
2006 -19.680.553 57.53%
2007 -23.335.332 15.66%
2008 -12.307.000 -89.61%
2009 34.878.000 135.29%
2010 -26.840.000 229.95%
2011 -20.263.000 -32.46%
2012 -43.493.000 53.41%
2013 -35.927.000 -21.06%
2014 -17.308.000 -107.57%
2015 -9.101.000 -90.18%
2016 -29.683.000 69.34%
2017 -9.107.000 -225.94%
2018 -10.623.000 14.27%
2019 -15.216.000 30.19%
2020 -13.474.000 -12.93%
2021 -29.440.000 54.23%
2022 -37.549.000 21.6%
2023 -5.136.000 -631.09%
2023 -24.479.000 79.02%
2024 -4.921.000 -397.44%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Achieve Life Sciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1994 700.000
1995 300.000 -133.33%
1996 500.000 40%
1997 1.200.000 58.33%
1998 500.000 -140%
1999 0 0%
2000 38.666 100%
2001 188.182 79.45%
2002 904.933 79.2%
2003 686.636 -31.79%
2004 426.001 -61.18%
2005 119.443 -256.66%
2006 789.386 84.87%
2007 1.396.057 43.46%
2008 3.000 -46435.23%
2009 15.000 80%
2010 68.000 77.94%
2011 79.000 13.92%
2012 291.000 72.85%
2013 253.000 -15.02%
2014 82.000 -208.54%
2015 371.000 77.9%
2016 46.000 -706.52%
2017 0 0%
2018 46.000 100%
2019 53.000 13.21%
2020 17.000 -211.76%
2021 17.000 0%
2022 0 0%
2023 0 0%
2023 21.000 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Achieve Life Sciences, Inc. Equity
Year Equity Growth
1994 -9.000.000
1995 10.900.000 182.57%
1996 16.800.000 35.12%
1997 18.500.000 9.19%
1998 7.500.000 -146.67%
1999 10.000.000 25%
2000 8.509.477 -17.52%
2001 14.665.130 41.97%
2002 15.723.928 6.73%
2003 19.309.683 18.57%
2004 19.077.181 -1.22%
2005 35.263.792 45.9%
2006 43.041.937 18.07%
2007 31.904.417 -34.91%
2008 10.707.000 -197.98%
2009 22.959.000 53.36%
2010 44.125.000 47.97%
2011 30.890.000 -42.85%
2012 66.207.000 53.34%
2013 37.211.000 -77.92%
2014 34.059.000 -9.25%
2015 37.440.000 9.03%
2016 18.966.000 -97.41%
2017 7.879.000 -140.72%
2018 15.802.000 50.14%
2019 18.050.000 12.45%
2020 37.286.000 51.59%
2021 28.042.000 -32.96%
2022 8.303.000 -237.73%
2023 4.038.000 -105.62%
2023 -1.448.000 378.87%
2024 42.285.000 103.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Achieve Life Sciences, Inc. Assets
Year Assets Growth
1994 3.200.000
1995 19.600.000 83.67%
1996 26.800.000 26.87%
1997 28.900.000 7.27%
1998 18.800.000 -53.72%
1999 18.100.000 -3.87%
2000 14.309.820 -26.49%
2001 15.863.682 9.8%
2002 17.934.303 11.55%
2003 21.468.240 16.46%
2004 22.570.599 4.88%
2005 57.913.914 61.03%
2006 68.493.002 15.45%
2007 45.249.269 -51.37%
2008 14.790.000 -205.95%
2009 68.980.000 78.56%
2010 89.918.000 23.29%
2011 68.015.000 -32.2%
2012 82.016.000 17.07%
2013 55.689.000 -47.28%
2014 56.291.000 1.07%
2015 58.209.000 3.3%
2016 27.470.000 -111.9%
2017 9.892.000 -177.7%
2018 19.084.000 48.17%
2019 21.078.000 9.46%
2020 40.298.000 47.69%
2021 47.516.000 15.19%
2022 29.971.000 -58.54%
2023 24.337.000 -23.15%
2023 19.371.000 -25.64%
2024 64.791.000 70.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Achieve Life Sciences, Inc. Liabilities
Year Liabilities Growth
1994 12.200.000
1995 8.700.000 -40.23%
1996 10.000.000 13%
1997 10.400.000 3.85%
1998 11.300.000 7.96%
1999 8.100.000 -39.51%
2000 5.800.343 -39.65%
2001 1.198.552 -383.95%
2002 2.210.375 45.78%
2003 2.158.557 -2.4%
2004 3.493.418 38.21%
2005 22.650.122 84.58%
2006 25.451.065 11.01%
2007 13.344.852 -90.72%
2008 4.083.000 -226.84%
2009 46.021.000 91.13%
2010 45.793.000 -0.5%
2011 37.125.000 -23.35%
2012 15.809.000 -134.83%
2013 18.478.000 14.44%
2014 22.232.000 16.89%
2015 20.769.000 -7.04%
2016 8.504.000 -144.23%
2017 2.013.000 -322.45%
2018 3.282.000 38.67%
2019 3.028.000 -8.39%
2020 3.012.000 -0.53%
2021 19.474.000 84.53%
2022 21.668.000 10.13%
2023 20.299.000 -6.74%
2023 20.819.000 2.5%
2024 22.506.000 7.5%

Achieve Life Sciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.8
Price to Earning Ratio
-6.57x
Price To Sales Ratio
0x
POCF Ratio
-9.18
PFCF Ratio
-9.17
Price to Book Ratio
4.28
EV to Sales
0
EV Over EBITDA
-7.27
EV to Operating CashFlow
-9.33
EV to FreeCashFlow
-9.32
Earnings Yield
-0.15
FreeCashFlow Yield
-0.11
Market Cap
0,18 Bil.
Enterprise Value
0,18 Bil.
Graham Number
4.72
Graham NetNet
1.13

Income Statement Metrics

Net Income per Share
-0.8
Income Quality
0.72
ROE
-1.17
Return On Assets
-0.69
Return On Capital Employed
-0.46
Net Income per EBT
1
EBT Per Ebit
1.75
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.57
Free CashFlow per Share
-0.57
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.09
Return on Invested Capital
-0.43
Return on Tangible Assets
-0.44
Days Sales Outstanding
0
Days Payables Outstanding
740.77
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.49
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,79
Book Value per Share
1,23
Tangible Book Value per Share
1.17
Shareholders Equity per Share
1.23
Interest Debt per Share
0.51
Debt to Equity
0.42
Debt to Assets
0.27
Net Debt to EBITDA
-0.11
Current Ratio
4.56
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
50972000
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Achieve Life Sciences, Inc. Dividends
Year Dividends Growth

Achieve Life Sciences, Inc. Profile

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

CEO
Dr. Richard A. B. Stewart
Employee
22
Address
1040 West Georgia Street
Vancouver, V6E 4H1

Achieve Life Sciences, Inc. Executives & BODs

Achieve Life Sciences, Inc. Executives & BODs
# Name Age
1 Dr. Richard A. B. Stewart
Chief Executive Officer & Executive Director
70
2 Dr. Cindy Jacobs M.D., Ph.D.
President, Chief Medical Officer & Director
70
3 Mr. Thomas B. King M.B.A.
Executive Chairman
70
4 Dr. Anthony Clarke Ph.D.
Chief Scientific Officer
70
5 Mr. Mark K. Oki CPA
Chief Financial Officer
70
6 Ms. Jaime Xinos
Chief Commercial Officer
70
7 Dr. Mark L. Rubinstein
Head of Medical Affairs
70
8 Mr. Craig Donnelly
Executive Vice President of CMC & Regulatory CMC
70
9 Mr. Jerry Wan
Principal Accounting Officer
70

Achieve Life Sciences, Inc. Competitors